Mohd Farizh Che Pa, Ng Tiang Koi, Arisah Misnan, Farida Hanim Islahudin, Mohd Makmor-Bakry
Background Antiretroviral therapy (ART) is used in human immunodeficiency virus (HIV) treatment to reduce morbidity and mortality rates among people living with the virus. The types of drug-related problems (DRPs) and their causes that contributed to HIV treatment failure were unknown. Thus, this study aimed to determine the types and causes of DRPs associated with HIV treatment failure. Methods A multicentre, retrospective cohort study was conducted at the Infectious Disease Centre of Sungai Buloh Hospital, Selangor, and Tuanku Ja'afar Hospital, Negeri Sembilan. Data were collected from patients' medical records by reviewing the medical progress notes, laboratory parameters, and treatment regimen. Pharmaceutical Care Network of Europe's (PCNE) classification system V9.1 was used to identify and classify the types and causes of DRPs. Patients were classified as having treatment failure if the HIV RNA viral load was more than 1000 copies/ml for two consecutive readings. Patients were categorized as treatment successful if there was a decrease in HIV RNA viral load suppression after six months of ART initiation and had no history of persistent HIV RNA viral load greater than 1000 copies/ml for two consecutive measurements. Data were analyzed using the chi-square test. Results The number of patients recruited for this study was 355 (treatment success group = 263, treatment failure group = 92). Almost all patients (n = 354, 99.7%) had experienced at least one DRP. A total of 811 problems and 1605 causes of DRPs were encountered. The occurrence of DRPs in the HIV treatment failure group was 5.77 DRPs per patient compared to the success group (4.08 DRPs per patient). In the treatment failure group, treatment effectiveness was identified as the most frequent domain of problems (P) (P1: n = 169, 59.93%), followed by treatment safety (P2: n = 111, 39.36%). The common domains of causes (C) include patient-related (C7: n = 367, 69.11%), other (C9: n = 105, 19.77%), and drug selection (C1: n = 49, 9.23%). Significant differences were found in several causes (C7.1, C7.10, and C9.1) between the two groups. Conclusion The occurrence of DRPs in HIV treatment failure was high, contributing to treatment effectiveness and treatment safety issues.
J Pharm Pract. 2020 Dec;33(6):820-826
[PMID:
31057060]
Health Aff (Millwood). 2019 Jul;38(7):1163-1172
[PMID:
31260344]
Adv Ther. 2016 Nov;33(11):1867-1884
[PMID:
27664109]
HIV Clin Trials. 2015 Jan-Feb;16(1):30-8
[PMID:
25777187]
Saudi Pharm J. 2017 Jul;25(5):724-733
[PMID:
28725145]
Am J Health Syst Pharm. 2008 Jan 1;65(1):55-9
[PMID:
18159040]
AIDS Behav. 2020 Jun;24(6):1727-1742
[PMID:
31673913]
Complement Ther Med. 2017 Dec;35:14-19
[PMID:
29154059]
Lancet HIV. 2018 Oct;5(10):e588-e596
[PMID:
30193863]
HIV AIDS (Auckl). 2022 Apr 13;14:155-165
[PMID:
35444470]
Afr Health Sci. 2020 Jun;20(2):560-567
[PMID:
33163017]
N Engl J Med. 2009 Apr 30;360(18):1815-26
[PMID:
19339714]
Antiviral Res. 2018 Jul;155:76-88
[PMID:
29758235]
Pharm Pract (Granada). 2015 Jan-Mar;13(1):512
[PMID:
25883687]
BMC Immunol. 2018 Dec 17;19(1):37
[PMID:
30558580]
Sci Rep. 2023 Mar 14;13(1):4183
[PMID:
36918596]
Br J Clin Pharmacol. 2015 Feb;79(2):182-94
[PMID:
24730660]
PLoS One. 2019 Dec 12;14(12):e0226293
[PMID:
31830095]
Int J Clin Pharm. 2020 Aug;42(4):1237-1241
[PMID:
32607718]
Ther Clin Risk Manag. 2022 Dec 02;18:1069-1079
[PMID:
36483091]
Curr HIV Res. 2018;16(6):436-446
[PMID:
30767743]
N Engl J Med. 1998 Mar 26;338(13):853-60
[PMID:
9516219]
Ethiop J Health Sci. 2019 Nov;29(6):751-758
[PMID:
31741646]
Front Public Health. 2022 Oct 25;10:916454
[PMID:
36408009]
PLoS One. 2019 Feb 5;14(2):e0211344
[PMID:
30721233]
BMC Pharmacol Toxicol. 2021 Oct 26;22(1):65
[PMID:
34702348]
J Infect Dis. 2011 Oct 15;204(8):1191-201
[PMID:
21917892]
Ann Pharmacother. 2015 Apr;49(4):405-18
[PMID:
25614526]
Antivir Ther. 2012;17(8):1495-502
[PMID:
22878339]
Ethiop J Health Sci. 2017 Feb;27(Suppl 1):39-52
[PMID:
28465652]
PLoS One. 2014 May 15;9(5):e97482
[PMID:
24830290]
N Engl J Med. 2009 Dec 3;361(23):2230-40
[PMID:
19952143]
AIDS. 2018 Jan 2;32(1):17-23
[PMID:
29112073]
AIDS. 2003 Sep 5;17(13):1925-32
[PMID:
12960825]
J Altern Complement Med. 2010 Nov;16(11):1171-6
[PMID:
20973734]
AIDS Behav. 2023 May;27(5):1441-1468
[PMID:
36318429]
AIDS Res Ther. 2017 Feb 1;14(1):5
[PMID:
28143541]
BMC Infect Dis. 2020 Jul 1;20(1):460
[PMID:
32611405]
Ther Clin Risk Manag. 2014 Aug 07;10:631-9
[PMID:
25120369]
Afr Health Sci. 2021 Mar;21(1):263-272
[PMID:
34394306]
Pharmaceutics. 2023 Oct 18;15(10):
[PMID:
37896248]
PLoS One. 2016 Oct 13;11(10):e0164619
[PMID:
27736953]
J Acquir Immune Defic Syndr. 2015 Aug 15;69(5):551-9
[PMID:
25886927]
HIV Med. 2012 Apr;13(4):193-201
[PMID:
22107359]
HIV Med. 2010 Jan;11(1):31-9
[PMID:
19601993]
Ann Pharmacother. 2004 Apr;38(4):550-6
[PMID:
14990778]
Expert Rev Clin Pharmacol. 2017 Dec;10(12):1329-1352
[PMID:
28922979]
SAGE Open Med. 2021 Apr 16;9:20503121211009728
[PMID:
33948177]
Clin Microbiol Infect. 2020 Sep;26(9):1161-1170
[PMID:
32360208]
Jpn J Infect Dis. 2016;69(1):56-9
[PMID:
26073728]
J Clin Epidemiol. 1996 Dec;49(12):1373-9
[PMID:
8970487]
Perspect Clin Res. 2020 Oct-Dec;11(4):158-163
[PMID:
33489833]
